PT2344637E - Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne - Google Patents

Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne Download PDF

Info

Publication number: PT2344637E
Authority: PT; Portugal
Prior art keywords: exon; mrna; methods; muscular dystrophy; duchenne muscular
Prior art date: 2008-10-27

Application number

PT09788160T

Other languages

English (en)

Inventor

Garrit-Jan Boudewijn Van Ommen

Gerardus Johannes Platenburg

Josephus Johannes De Kimpe

Judith Christina Theodora Van Deutekom

Annemieke Aartsma-Rus

Original Assignee

Academisch Ziekenhuis Leiden

Prosensa Technologies Bv

Prosensa Bv

Prosensa Holding Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-27

Filing date

2009-01-13

Publication date

2015-03-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40873329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2344637(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-27 Priority claimed from PCT/NL2008/050673 external-priority patent/WO2009054725A2/en

2009-01-13 Application filed by Academisch Ziekenhuis Leiden, Prosensa Technologies Bv, Prosensa Bv, Prosensa Holding Bv filed Critical Academisch Ziekenhuis Leiden

2015-03-23 Publication of PT2344637E publication Critical patent/PT2344637E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PT09788160T 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne PT2344637E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/NL2008/050673 WO2009054725A2 (en)	2007-10-26	2008-10-27	Means and methods for counteracting muscle disorders

Publications (1)

Publication Number	Publication Date
PT2344637E true PT2344637E (pt)	2015-03-23

Family

ID=40873329

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT131603383T PT2607484E (pt)	2008-10-27	2009-01-13	Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
PT09788160T PT2344637E (pt)	2008-10-27	2009-01-13	Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT131603383T PT2607484E (pt)	2008-10-27	2009-01-13	Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne

Country Status (15)

Country	Link
EP (4)	EP2607484B1 (pt)
JP (2)	JP5786109B2 (pt)
AU (1)	AU2009310557B2 (pt)
CA (3)	CA2741629C (pt)
CY (1)	CY1116305T1 (pt)
DK (2)	DK2344637T4 (pt)
ES (2)	ES2532634T5 (pt)
HK (1)	HK1160169A1 (pt)
HR (1)	HRP20160078T1 (pt)
IL (2)	IL212509A (pt)
NZ (1)	NZ592498A (pt)
PL (1)	PL2607484T3 (pt)
PT (2)	PT2607484E (pt)
SI (1)	SI2607484T1 (pt)
WO (2)	WO2010050801A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1766010T3 (pl)	2004-06-28	2011-07-29	Univ Western Australia	Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
USRE48960E1 (en)	2004-06-28	2022-03-08	The University Of Western Australia	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP3238737B1 (en)	2007-10-26	2022-04-06	Academisch Ziekenhuis Leiden	Means and methods for counteracting muscle disorders
EP2119783A1 (en)	2008-05-14	2009-11-18	Prosensa Technologies B.V.	Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP3428278A1 (en)	2008-10-24	2019-01-16	Sarepta Therapeutics, Inc.	Multiple exon skipping compositions for dmd
WO2011036640A2 (en) *	2009-09-24	2011-03-31	Cellectis	Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
PT2499249T (pt)	2009-11-12	2018-11-21	Univ Western Australia	Moléculas antisentido e métodos para tratar patologias
TWI541024B (zh)	2010-09-01	2016-07-11	日本新藥股份有限公司	反義核酸
WO2012109296A1 (en) *	2011-02-08	2012-08-16	The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center	Antisense oligonucleotides
AU2012360702C1 (en)	2011-12-28	2018-09-20	National Center Of Neurology And Psychiatry	Antisense nucleic acid
CN112251436A (zh) *	2012-01-27	2021-01-22	比奥马林技术公司	治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP3608407A1 (en) *	2012-07-03	2020-02-12	BioMarin Technologies B.V.	Oligonucleotide for the treatment of muscular dystrophy patients
CN105378081B (zh)	2013-03-14	2019-06-14	萨勒普塔医疗公司	用于治疗肌营养不良的外显子跳跃组合物
BR112015022998A2 (pt)	2013-03-15	2017-11-14	Sarepta Therapeutics Inc	composições melhoradas para o tratamento de distrofia muscular
US11236338B2 (en) *	2013-09-05	2022-02-01	Sarepta Therapeutics, Inc.	Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP6519842B2 (ja) *	2013-10-04	2019-05-29	国立大学法人神戸大学	福山型筋ジストロフィー治療用アンチセンス核酸
UA120849C2 (uk) *	2014-03-12	2020-02-25	Ніппон Шин'Яку Ко., Лтд.	Антисенсовий олігомер
HRP20220379T1 (hr)	2014-06-10	2022-05-27	Erasmus University Medical Center Rotterdam	Antisense oligonukleotidi korisni u liječenju pompeove bolesti
PL3351633T3 (pl) *	2015-09-15	2020-11-02	Nippon Shinyaku Co., Ltd.	Antysensowny kwas nukleinowy
US20190127733A1 (en)	2015-10-09	2019-05-02	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
CN108778344A (zh) *	2016-03-02	2018-11-09	里兰斯坦福初级大学理事会	抗流感病毒的泛基因型药剂和其使用方法
US11339392B2 (en)	2016-03-02	2022-05-24	The Board Of Trustees Of The Leland Stanford Junior University	Pan-genotypic agents against influenza virus and methods of using the same
MA45328A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Compositions acide nucléique-polypeptide et utilisations de celles-ci
AU2017254106B2 (en)	2016-04-18	2024-07-11	Sarepta Therapeutics, Inc.	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
MA45290A (fr) *	2016-05-04	2019-03-13	Wave Life Sciences Ltd	Procédés et compositions d'agents biologiquement actifs
MX2018016052A (es)	2016-06-30	2019-05-02	Sarepta Therapeutics Inc	Oligomeros de omision de exon para distrofia muscular.
AU2017291960B2 (en) *	2016-07-05	2024-03-14	Biomarin Technologies B.V.	Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
MX2019006882A (es)	2016-12-19	2019-08-16	Sarepta Therapeutics Inc	Conjugados de oligomeros de omision de exon para distrofia muscular.
MX2019006989A (es)	2016-12-19	2019-08-16	Sarepta Therapeutics Inc	Conjugados de oligomeros de omision de exon para distrofia muscular.
EP4115908A1 (en)	2016-12-19	2023-01-11	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
KR20190104381A (ko)	2017-01-06	2019-09-09	어비디티 바이오사이언시스 엘엘씨	핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20210145852A1 (en)	2017-09-28	2021-05-20	Sarepta Therapeutics, Inc.	Combination Therapies for Treating Muscular Dystrophy
WO2019071028A1 (en)	2017-10-04	2019-04-11	Avidity Biosciences Llc	NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
EP3720448A4 (en)	2017-12-06	2021-11-03	Avidity Biosciences, Inc.	COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
JP2021526796A (ja) *	2018-06-13	2021-10-11	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーに対するエクソンスキッピングオリゴマー
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2019316103A1 (en)	2018-08-02	2021-03-11	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20210081322A (ko)	2018-08-02	2021-07-01	다인 세라퓨틱스, 인크.	근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
WO2020118246A1 (en) *	2018-12-06	2020-06-11	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
US11578090B2 (en)	2019-06-06	2023-02-14	Avidity Biosciences, Inc.	Nucleic acid-polypeptide compositions and uses thereof
WO2020247818A1 (en)	2019-06-06	2020-12-10	Avidity Biosciences, Inc.	Una amidites and uses thereof
US20230045557A1 (en) *	2019-12-19	2023-02-09	Nippon Shinyaku Co., Ltd.	Antisense nucleic acid enabling exon skipping
CN118109468A (zh)	2019-12-26	2024-05-31	日本新药株式会社	诱导外显子50的跳读的反义核酸
MX2022010545A (es)	2020-02-28	2022-09-21	Nippon Shinyaku Co Ltd	Acidos nucleicos antisentido que inducen la omision del exon 51.
AU2021237465A1 (en)	2020-03-19	2022-10-13	Avidity Biosciences, Inc.	Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11638761B2 (en)	2021-07-09	2023-05-02	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309028A1 (en)	2021-07-09	2024-01-25	Dyne Therapeutics, Inc.	Muscle targeting complexes and formulations for treating dystrophinopathies
AU2022424485A1 (en)	2021-12-27	2024-07-11	Nippon Shinyaku Co., Ltd.	Method for producing oligonucleic acid compound
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60042338D1 (de)	1999-10-04	2009-07-16	Univ New Jersey Med	TAR RNA bindende Peptide
JP4836366B2 (ja) *	2000-08-25	2011-12-14	雅文松尾	デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) *	2000-08-25	2004-04-27	Jcr Pharmaceuticals Co., Ltd.	Pharmaceutical composition for treatment of Duchenne muscular dystrophy
WO2004083432A1 (en) *	2003-03-21	2004-09-30	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
PL1766010T3 (pl) *	2004-06-28	2011-07-29	Univ Western Australia	Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
AU2006237727B2 (en) *	2005-04-22	2012-06-28	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mRNA by interfering with the binding of SR proteins and by interfering with secondary RNA structure.
EP1857548A1 (en) *	2006-05-19	2007-11-21	Academisch Ziekenhuis Leiden	Means and method for inducing exon-skipping
EP3238737B1 (en)	2007-10-26	2022-04-06	Academisch Ziekenhuis Leiden	Means and methods for counteracting muscle disorders
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
EP3428278A1 (en) *	2008-10-24	2019-01-16	Sarepta Therapeutics, Inc.	Multiple exon skipping compositions for dmd
US9607308B2 (en)	2011-06-29	2017-03-28	American Express Travel Related Services Company, Inc.	Spend based digital ad targeting and measurement

2009
- 2009-01-13 CA CA2741629A patent/CA2741629C/en active Active
- 2009-01-13 PL PL13160338T patent/PL2607484T3/pl unknown
- 2009-01-13 SI SI200931381A patent/SI2607484T1/sl unknown
- 2009-01-13 DK DK09788160.1T patent/DK2344637T4/en active
- 2009-01-13 EP EP13160338.3A patent/EP2607484B1/en not_active Revoked
- 2009-01-13 EP EP09788160.1A patent/EP2344637B2/en active Active
- 2009-01-13 ES ES09788160.1T patent/ES2532634T5/es active Active
- 2009-01-13 WO PCT/NL2009/050006 patent/WO2010050801A1/en active Application Filing
- 2009-01-13 PT PT131603383T patent/PT2607484E/pt unknown
- 2009-01-13 JP JP2011533126A patent/JP5786109B2/ja active Active
- 2009-01-13 ES ES13160338.3T patent/ES2562658T3/es active Active
- 2009-01-13 AU AU2009310557A patent/AU2009310557B2/en active Active
- 2009-01-13 PT PT09788160T patent/PT2344637E/pt unknown
- 2009-01-13 DK DK13160338.3T patent/DK2607484T3/en active
- 2009-03-11 EP EP18180952.6A patent/EP3400948B1/en active Active
- 2009-03-11 NZ NZ592498A patent/NZ592498A/en unknown
- 2009-03-11 WO PCT/NL2009/050113 patent/WO2010050802A2/en active Application Filing
- 2009-03-11 EP EP09788170.0A patent/EP2349287B1/en active Active
- 2009-03-11 CA CA2741793A patent/CA2741793C/en active Active
- 2009-03-11 JP JP2011533127A patent/JP5905260B2/ja active Active
- 2009-03-11 CA CA3017539A patent/CA3017539A1/en active Pending
2011
- 2011-04-27 IL IL212509A patent/IL212509A/en active IP Right Grant
- 2011-04-27 IL IL212508A patent/IL212508A/en active IP Right Grant
2012
- 2012-01-16 HK HK12100495.6A patent/HK1160169A1/xx active IP Right Maintenance
2015
- 2015-03-04 CY CY20151100228T patent/CY1116305T1/el unknown
2016
- 2016-01-25 HR HRP20160078TT patent/HRP20160078T1/hr unknown

Also Published As

Publication number	Publication date
IL212509A0 (en)	2011-06-30
EP3400948B1 (en)	2022-11-02
IL212508A0 (en)	2011-06-30
JP5786109B2 (ja)	2015-09-30
CA2741793A1 (en)	2010-05-06
WO2010050802A2 (en)	2010-05-06
CA3017539A1 (en)	2010-05-06
AU2009310558A1 (en)	2010-05-06
WO2010050802A3 (en)	2010-08-12
CA2741793C (en)	2018-10-30
JP2012506697A (ja)	2012-03-22
EP2344637B1 (en)	2014-12-24
EP2344637B2 (en)	2018-02-28
CA2741629C (en)	2022-07-05
DK2344637T3 (en)	2015-02-02
EP2607484B1 (en)	2016-01-06
ES2532634T5 (es)	2018-04-30
AU2009310557B2 (en)	2014-09-11
DK2344637T4 (en)	2018-04-23
CA2741629A1 (en)	2010-05-06
HK1160169A1 (en)	2012-08-10
ES2532634T3 (es)	2015-03-30
AU2009310558B2 (en)	2014-09-04
EP2344637A1 (en)	2011-07-20
IL212509A (en)	2016-04-21
CY1116305T1 (el)	2017-02-08
HRP20160078T1 (hr)	2016-04-08
JP5905260B2 (ja)	2016-04-20
EP2349287B1 (en)	2018-08-15
IL212508A (en)	2013-11-28
EP3400948A1 (en)	2018-11-14
JP2012506698A (ja)	2012-03-22
NZ592498A (en)	2012-05-25
PT2607484E (pt)	2016-03-09
EP2607484A1 (en)	2013-06-26
DK2607484T3 (en)	2016-03-07
AU2009310558A8 (en)	2015-01-22
EP2349287A2 (en)	2011-08-03
SI2607484T1 (sl)	2016-11-30
AU2009310557A1 (en)	2010-05-06
PL2607484T3 (pl)	2016-06-30
AU2009310557A8 (en)	2011-09-29
ES2562658T3 (es)	2016-03-07
WO2010050801A1 (en)	2010-05-06

Publication	Publication Date	Title
IL212508A0 (en)	2011-06-30	Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
IL282772A (en)	2021-06-30	Methods for efficient deletion of exon 44 in patients and means involved in this
HK1185098A1 (zh)	2014-02-07	高效跳過裘馨氏肌肉營養不良症前體外顯子的方法和工具
IL278833A (en)	2021-01-31	Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
HK1149338A1 (en)	2011-09-30	Methods and apparatus for decreasing power consumption and bus activity
GB0715938D0 (en)	2007-09-26	Method of treatment of duchenne muscular dystrophy
EP2247950A4 (en)	2011-04-13	METHODS AND COMPOSITIONS FOR DETECTING MICROORGANISMS
ZA201100651B (en)	2012-02-29	Method for dispersing and separating nanotubes
GB0818401D0 (en)	2008-11-12	Fastener feed method and apparatus
HK1160721A1 (en)	2012-08-17	Methods and apparatuses for plant aeration
HK1132307A1 (en)	2010-02-19	Electroplating device and method for electroplating
EP2190986A4 (en)	2012-01-11	HYBRIDIZATION METHOD AND APPARATUS
EP2340315A4 (en)	2012-04-25	COMPOSITIONS AND METHODS FOR DETECTION OF JAK2 NUCLEIC ACID MUTATIONS
IL209324A0 (en)	2011-01-31	Aliskiren monofumarate and processes for preparation thereof
EP2495040A4 (en)	2015-12-16	AGITATOR DEVICE AND STIRRER HOOKS FOR THE SAME
GB0817991D0 (en)	2008-11-05	Fluorescence based detection methods and apparatus
EP2330950A4 (en)	2012-10-24	LOCKABLE LOCHWORK MOUNTING AND METHOD
TWI368845B (en)	2012-07-21	Multimedia palying method and apparatus thereof
TWI371971B (en)	2012-09-01	De-interlacing method and apparatus
TWI347126B (en)	2011-08-11	Dynamic de-interlacing method and apparatus
GB0713944D0 (en)	2007-08-29	In-Vessel composting apparatus and method
GB0614690D0 (en)	2006-08-30	Method of treatment of duchenne muscular dystrophy
IL208372A0 (en)	2010-12-30	Fatty acid amides and uses thereof